Floatz logo

Phesgo / / 20,000 Unt In

HER2-positive Breast Cancer

Hoffmann-La RochePhase 1/2Active
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
65/ 100

Competitive context

129 Active assets in the HER2-positive Breast Cancer cohort.

Asset / SponsorPhaseRating
IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MOUSE MONOCLONAL 2C4 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 2C4 .KAPPA.-CHAIN, DIMER
SWOG Cancer Research Network
Phase 4BB
TRASTUZUMAB
SWOG Cancer Research Network
Phase 4BB
Capecitabine
MedSIR
Phase 4BB
Vinorelbine
Fudan University
Phase 3BB
Docetaxel
Ohio State University Comprehensive Cancer Center
Phase 3BB

View all 50 →

Same molecule, other indications

Phesgo / / 20,000 Unt In is also rated in:

Advanced Solid TumorsDormant
CC
Indicative ·
40 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →